Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 12/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.44 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16015437 | 0.88 | CHRNB2 (0.46) | EPHX2EPHX1ALDH1A1CHRNB2CHRNA3 | |
| SCHEMBL25633195 | 0.88 | CHRNB2 (0.46) | EPHX2EPHX1ALDH1A1CHRNB2CHRNA3 | |
| SCHEMBL16077702 | 0.87 | EPHX2 (0.51) | EPHX2EPHX1ALDH1A1CHRNB2CHRNA3 | |
| SCHEMBL621450 | 0.85 | EPHX2 (0.50) | EPHX2EPHX1ALDH1A1CHRNB2CHRNA3 | |
| SCHEMBL4578708 | 0.85 | EPHX2 (0.50) | EPHX2EPHX1ALDH1A1CHRNB2CHRNA3 | |
| SCHEMBL12424480 | 0.85 | ALDH1A1 (0.42) | EPHX2ALDH1A1NPC1GNAI3GNAO1 | |
| SCHEMBL10305557 | 0.83 | EPHX2 (0.49) | EPHX2EPHX1ALDH1A1 | |
| SCHEMBL4518519 | 0.83 | GNAI3 (0.51) | EPHX2EPHX1ALDH1A1CHRNB2CHRNA3 | |
| SCHEMBL6029465 | 0.83 | EPHX2 (0.49) | EPHX2EPHX1ALDH1A1CHRNB2CHRNA3 | |
| SCHEMBL3317695 | 0.83 | EPHX2 (0.49) | EPHX2EPHX1ALDH1A1CHRNB2CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024073626-A2 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
| US-11033539-B2 | Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| EP-3715346-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | Dana-Farber Cancer Institute (US) | 2020-09-30 | — | — | EP | disclosed |
| US-20170233411-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20150353495-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | ALEXION PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | disclosed |
| US-9169224-B2 | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-27 | — | — | US | disclosed |
| US-9102625-B2 | Nicotinamides as JAK kinase modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-8580848-B2 | Benzofuran type derivatives, a composition comprising the same for treating or preventing cognitive dysfunction and the use thereof | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-11-12 | — | — | US | disclosed |
| US-8507553-B2 | Benzofuran type derivatives, a composition comprising the same for treating or preventing cognitive dysfunction and the use thereof | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-08-13 | — | — | US | disclosed |
| US-8455542-B2 | Benzofuran type derivatives, a composition comprising the same for treating or preventing cognitive dysfunction and the use thereof | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-06-04 | — | — | US | disclosed |
| US-20120259006-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | DAEWOONG PHARMACEUTICAL CO., LTD (KR) | 2012-10-11 | — | — | US | disclosed |
| US-20120245165-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | DAEWOONG PHARMACEUTICAL CO., LTD (KR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245225-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | DAEWOONG PHARMACEUTICAL CO., LTD (KR) | 2012-09-27 | — | — | US | disclosed |
| US-8263649-B2 | Benzofuran type derivatives, a composition comprising the same for treating or preventing cognitive dysfunction and the use thereof | MEDIFRON DBT CO., LTD. (KR) | 2012-09-11 | — | — | US | disclosed |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20100197685-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | DIGITAL BIOTECH CO., LTD (KR) | 2010-08-05 | — | — | US | disclosed |
| US-20080182783-A1 | Growth Hormone Conjugates | NOVO NORDISK A/S (DK) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11033539-B2 | Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases | CHRM2, CHRM4, CHRM1 | EPHX2 1479/4885EPHX1 1532/4885ALDH1A1 4256/4885 |
| US-20170233411-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | BTK, BCL9L, BCL9 | EPHX2 3082/4885EPHX1 2537/4885ALDH1A1 3889/4885 |
| US-20100197685-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | APP, BACE1, PSEN1 | EPHX2 2659/4885EPHX1 1206/4885ALDH1A1 770/4885 |
| US-20120259006-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | APP, BACE1, PSEN1 | EPHX2 2659/4885EPHX1 1206/4885ALDH1A1 770/4885 |
| US-20080182783-A1 | Growth Hormone Conjugates | GHRHR, GHSR, GHITM | EPHX2 1935/4885EPHX1 3058/4885ALDH1A1 1553/4885 |
| US-20120245165-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | APP, BACE1, PSEN1 | EPHX2 2659/4885EPHX1 1206/4885ALDH1A1 770/4885 |
| US-20150353495-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | EPHX2 2126/4885EPHX1 1367/4885ALDH1A1 780/4885 |
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | YTHDF1, YTHDF3, YTHDF2 | EPHX2 4161/4885EPHX1 4134/4885ALDH1A1 4553/4885 |
| US-20120245225-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | APP, BACE1, PSEN1 | EPHX2 2659/4885EPHX1 1206/4885ALDH1A1 770/4885 |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | EPHX2 2126/4885EPHX1 1367/4885ALDH1A1 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.